This is the first time to our knowledge that a CDH6-targeted ADC has demonstrated antitumor efficacy in settings other than ovarian cancer and RCC and indicate CUSP06 could have therapeutic potential in CDH6-positive uterine cancer and cholangiocarcinoma patients. This evidence concerns the gene CDH6 and renal cell carcinoma.